Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE vs ABRILADA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Articaine is an amide local anesthetic that blocks sodium ion channels in nerve cell membranes, preventing depolarization and conduction of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the anesthetic effect by reducing local blood flow and systemic absorption.
Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including changes in adhesion molecules, chemotaxis, and apoptosis.
Local infiltration anesthesia for dental procedures,Nerve block anesthesia for dental procedures
Rheumatoid arthritis,Juvenile idiopathic arthritis,Psoriatic arthritis,Ankylosing spondylitis,Crohn's disease,Ulcerative colitis,Plaque psoriasis,Hidradenitis suppurativa,Uveitis
Adults: 1:100,000 epinephrine formulation (4% articaine) administered as a submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 m L/kg) per appointment, not to exceed 500 mg (12.5 m L). 1:200,000 epinephrine formulation may be used; maximum dose same.
80 mg subcutaneously every other week. For patients weighing ≥100 kg, 80 mg every week.
Articaine: terminal half-life ~20 minutes (0.33 h) in plasma; clinical context: rapid elimination limits systemic toxicity. Epinephrine: short half-life ~2 minutes; clinical effect terminated by uptake and metabolism.
Terminal elimination half-life approximately 10–14 days in adults, supporting every-other-week dosing; may be shorter in pediatric patients.
Articaine is primarily metabolized by plasma esterases (butyrylcholinesterase) to its inactive metabolite articainic acid. Epinephrine is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Adalimumab is a monoclonal antibody that is metabolized via catabolism into peptides and amino acids. CYP450 enzymes are not involved. No active metabolites.
Articaine is primarily metabolized by plasma esterases; its inactive metabolite articainic acid is excreted renally (approximately 90% as metabolites, <2% unchanged). Epinephrine is metabolized by COMT and MAO; metabolites and small amounts unchanged are excreted in urine (~90% renal).
Primarily degraded into amino acids and recycled or excreted in urine (less than 1% unchanged); no significant biliary/fecal elimination.
Articaine: ~60–80% bound to plasma proteins (primarily albumin). Epinephrine: ~50% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
Approximately 95% bound to serum proteins, primarily alpha-1-acid glycoprotein and albumin.
Articaine: Vd ~1.0 L/kg (healthy adults); large Vd indicates extensive tissue distribution. Epinephrine: Vd ~0.2 L/kg (predominantly in circulation and tissues).
Approximately 4.7–6.0 L/kg, indicating extensive distribution into tissues consistent with a monoclonal antibody.
Not applicable for submucosal injection (100% bioavailable locally). Oral epinephrine has negligible bioavailability due to first-pass metabolism. For systemic effects, IV administration yields 100% bioavailability.
Subcutaneous: approximately 64% (range 50–80%) absolute bioavailability relative to intravenous administration.
No dosage adjustment required for mild-to-moderate renal impairment; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of articaine metabolite; monitor for toxicity.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD; use with caution.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to reduced metabolism; consider reduced doses and monitor for prolonged effects.
No formal studies in hepatic impairment. Use with caution in moderate to severe impairment (Child-Pugh B or C) due to limited data.
Children ≥4 years: 4% articaine with 1:100,000 or 1:200,000 epinephrine; submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 m L/kg) per appointment, not to exceed 7 mg/kg (absolute max 500 mg). For 1:100,000 formulation, maximum epinephrine dose 0.001 mg/kg (0.001 m L/kg) per injection.
Approved for pediatric plaque psoriasis (≥12 years): 80 mg subcutaneously every other week. For pediatric psoriatic arthritis (≥12 years): 80 mg subcutaneously every other week. For pediatric hidradenitis suppurativa (≥12 years, ≥60 kg): 160 mg on day 1, then 80 mg every other week. Pediatric Crohn's disease (≥6 years, ≥40 kg): 160 mg on day 1, then 80 mg on day 15, then 80 mg every other week; for <40 kg: 80 mg on day 1, then 40 mg on day 15, then 40 mg every other week.
No specific dose adjustment; consider reduced doses due to age-related decreased hepatic and renal function; monitor for prolonged anesthesia and cardiovascular effects; use lowest effective dose.
No specific dose adjustment required; but monitor for infections in patients ≥65 years due to increased risk.
Not available
WARNING: SERIOUS INFECTIONS and MALIGNANCY. SERIOUS INFECTIONS: Patients treated with adalimumab are at increased risk for serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue adalimumab if a serious infection develops. MALIGNANCY: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab.
Risk of methemoglobinemia, especially in patients with glucose-6-phosphate dehydrogenase deficiency or hemoglobin abnormalities,Use with caution in patients with cardiovascular disease, hypertension, or hyperthyroidism due to epinephrine component,Avoid intravascular injection; may cause systemic toxicity or cardiovascular collapse,Caution in patients with hepatic or renal impairment,May cause allergic reactions or hypersensitivity; cross-sensitivity with other amide anesthetics is possible
Serious infections including tuberculosis, invasive fungal infections, and other opportunistic pathogens,Hepatitis B virus reactivation,Hypersensitivity reactions including anaphylaxis and angioneurotic edema,Neurologic events including new onset or exacerbation of demyelinating disorders,Hematologic events including pancytopenia and aplastic anemia,Congestive heart failure,Lupus-like syndrome,Malignancies including lymphoma, leukemia, and other malignancies
Hypersensitivity to articaine, epinephrine, or any component of the formulation,Hypersensitivity to amide-type local anesthetics,Patients with severe uncontrolled hypertension or hyperthyroidism,Patients with known sulfite sensitivity (epinephrine contains sodium metabisulfite),Do not use in patients with paroxysmal tachycardia or other serious arrhythmias
Known hypersensitivity to adalimumab or any inactive component of the product,Active serious infections including sepsis, tuberculosis, and opportunistic infections
No known food-drug interactions. Avoid eating until numbness resolves to prevent oral trauma.
No significant food interactions. Grapefruit and other CYP450 modulators do not affect adalimumab. Take without regard to meals.
FDA Pregnancy Category C. No well-controlled studies in pregnant women. In animal studies, articaine and epinephrine have not shown teratogenic effects at clinically relevant doses. Risk to fetus cannot be ruled out. Use only if clearly needed. No specific trimester-associated risks identified; however, epinephrine may reduce uteroplacental blood flow, particularly if given with vasoconstrictors or during second/third trimester.
Abrilada (adalimumab-adbm) is a TNF-alpha inhibitor. Limited human data; animal studies show no evidence of teratogenicity. Potential risk of increased infection in neonates exposed in utero. First trimester: Minimal known risk. Second/third trimester: May cross placenta; theoretical risk of immunosuppression.
Articaine and epinephrine are excreted into breast milk in low amounts. M/P ratio not available. The American Academy of Pediatrics considers articaine compatible with breastfeeding. However, theoretical risk of cardiovascular effects in infant exists. Use with caution, and advise mother to pump and discard milk for 4-6 hours after administration to minimize exposure.
Excreted in human milk in low concentrations; M/P ratio not well defined. Considered compatible with breastfeeding, but monitor infant for infection risks.
No specific dose adjustment required based on pharmacokinetic changes in pregnancy. However, due to increased plasma volume and cardiac output, higher doses may be needed to achieve adequate anesthesia? Typically, lowest effective dose is recommended. Avoid excessive epinephrine (max 0.1 mg per appointment) to minimize risk of uteroplacental vasoconstriction.
No dose adjustment routinely required; pregnancy may increase clearance, but no established guidelines for dose modification.
Aspirate before injection to prevent intravascular administration. Maximum dose: 7 mg/kg articaine (0.175 m L/kg of 4% solution with 1:100,000 epinephrine). Avoid in patients with hepatic porphyria. Use with caution in patients with sulfite allergy (epinephrine component contains sodium metabisulfite).
ABRILADA (adalimumab) is a TNF-alpha inhibitor. Monitor for latent TB reactivation with PPD or IGRA before initiation. Injection site reactions are common; rotate sites and apply cold compresses. Avoid live vaccines during therapy. Assess for new-onset or worsening heart failure, demyelinating disorders, and cytopenias. Increased risk of serious infections; screen for HBV, HCV, and fungal infections. Consider temporarily holding therapy for major surgical procedures.
You may experience temporary numbness of the tongue, lips, or face; avoid eating or drinking until sensation returns to prevent biting yourself.,Do not drive or operate machinery for at least 2 hours after administration, or until numbness resolves.,Contact your dentist or doctor immediately if you experience chest pain, difficulty breathing, rapid heartbeat, or severe headache after injection.,Inform your healthcare provider if you have heart disease, high blood pressure, thyroid problems, or are taking MAO inhibitors or tricyclic antidepressants.
Inspect injection site for redness, swelling, or itching; apply cold compress if needed.,Report signs of infection: fever, cough, painful urination, or skin wounds.,Avoid live vaccines (e.g., MMR, shingles, nasal flu) during treatment.,Review all current medications, including OTC and herbal supplements.,Notify healthcare provider before any planned surgery.,Use reliable contraception if of childbearing potential; continue 5 months after stopping.,Report new or worsening symptoms: shortness of breath, chest pain, numbness, vision changes.,Store ABRILADA in the refrigerator (36°F-46°F); do not freeze or shake.
"The concurrent use of acepromazine, a phenothiazine neuroleptic with significant α1-adrenergic receptor antagonism, and articaine, an amide local anesthetic, may result in enhanced hypotensive and arrhythmogenic effects. Acepromazine-induced vasodilation and decreased peripheral resistance, combined with articaine's potential for myocardial depression and conduction disturbances, particularly in cases of inadvertent intravascular injection, can precipitate severe hypotension and ventricular arrhythmias. Additionally, phenothiazines can potentiate the central nervous system depressant effects of local anesthetics, increasing the risk of sedation and respiratory depression."
"Coadministration of articaine, an amide local anesthetic that inhibits voltage-gated sodium channels, and levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may increase the risk of adverse cardiovascular effects, particularly hypertension and arrhythmias. The SNRI's enhancement of norepinephrine activity can potentiate sympathomimetic responses, while articaine's sodium channel blockade may exacerbate conduction abnormalities. This combination requires caution due to potential for additive cardiotoxicity."
"Dextropropoxyphene, a centrally acting opioid analgesic, may cause additive central nervous system depression and respiratory depression when combined with articaine, a local anesthetic. This interaction can lead to profound sedation, respiratory compromise, and increased risk of bradycardia and hypotension. Co-administration requires careful patient monitoring to prevent serious adverse outcomes, especially in elderly or debilitated patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE vs ABRILADA, answered by our medical review team.
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE is a Alpha/Beta Agonist that works by Articaine is an amide local anesthetic that blocks sodium ion channels in nerve cell membranes, preventing depolarization and conduction of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the anesthetic effect by reducing local blood flow and systemic absorption.. ABRILADA is a TNF-Alpha Inhibitor that works by Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including changes in adhesion molecules, chemotaxis, and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE and ABRILADA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE is: Adults: 1:100,000 epinephrine formulation (4% articaine) administered as a submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 m L/kg) per appointment, not to exceed 500 mg (12.5 m L). 1:200,000 epinephrine formulation may be used; maximum dose same.. The standard adult dose of ABRILADA is: 80 mg subcutaneously every other week. For patients weighing ≥100 kg, 80 mg every week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE and ABRILADA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE is classified as Category A/B. FDA Pregnancy Category C. No well-controlled studies in pregnant women. In animal studies, articaine and epinephrine have not shown teratogenic effects at clinically relevant doses. ABRILADA is classified as Category C. Abrilada (adalimumab-adbm) is a TNF-alpha inhibitor. Limited human data; animal studies show no evidence of teratogenicity. Potential risk of increased infection in neonates expose. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.